No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
MRK250117C105000
- 0.02
- -0.14-87.50%
15min DelayClose Jan 14 16:00 ET
0.14High0.01Low
0.14Open0.16Pre Close820 Volume10.19K Open Interest105.00Strike Price1.69KTurnover30.07%IV5.39%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.02Extrinsic Value100Contract SizeAmericanOptions Type0.0214Delta0.0202Gamma4982.50Leverage Ratio-0.0169Theta0.0002Rho106.75Eff Leverage0.0043Vega
Intraday
- 5D
- Daily
News
Jim Cramer Says He Supports Healthcare Stocks for Their Long-term Value
Boeing, NVIDIA Corp. Share Losses Lead Dow's 113-Point Drop
Merck Speeds Up Launch of New Keytruda Version as Patent Expiration Nears -- Barrons.com
BMO Capital Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $105
Jefferies Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $150
Merck & Co.'s Accelerated Keytruda Launch and Strategic Updates Bolster Long-term Growth Prospects